The clinical utility of human leucocyte antigen B27 in axial spondyloarthritis

Chong Seng Edwin Lim, Raj Sengupta, Karl Gaffney

Research output: Contribution to journalReview articlepeer-review

18 Citations (Scopus)


The association between HLA-B27 and AS was first established in the early 1970s. Since then, our understanding of this disease has changed, such that we now recognize AS to be the extreme of the clinical phenotype within a disease spectrum known as axial SpA (axSpA). Recent advances in therapeutic options have driven the need for earlier diagnosis and many screening strategies have been proposed to facilitate this. In parallel, our understanding of axSpA genetics, and especially the contribution of HLA-B27, has expanded. In this article we will present and discuss the evidence supporting the use of HLA-B27 in clinical practice. We will briefly summarize the evolution of the concept of axSpA, the prevalence of HLA-B27 and axSpA and the potential role of HLA-B27 in the aetiopathogenesis of axSpA and focus on the utility of HLA-B27 in everyday clinical practice.

Original languageEnglish
Pages (from-to)959-968
Number of pages10
Issue number6
Early online date25 Sep 2017
Publication statusPublished - 1 Jun 2018


  • Biological Factors/therapeutic use
  • Early Diagnosis
  • Genetic Markers
  • Genetic Testing/methods
  • Genetic Therapy/methods
  • HLA-B27 Antigen/genetics
  • Humans
  • Phenotype
  • Spondylarthritis/diagnosis

Cite this